CVE-2024-0758

CVE-2024-0758 is a medium-severity vulnerability in Ipb-halle Molecularfaces with a CVSS 3.x base score of 6.1. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-79.

Key facts

Description

MolecularFaces before 0.3.0 is vulnerable to cross site scripting. A remote attacker can execute arbitrary JavaScript in the context of a victim browser via crafted molfiles.

Frequently asked questions

What is CVE-2024-0758?
MolecularFaces before 0.3.0 is vulnerable to cross site scripting. A remote attacker can execute arbitrary JavaScript in the context of a victim browser via crafted molfiles.
How severe is CVE-2024-0758?
CVE-2024-0758 has a CVSS 3.x base score of 6.1, rated medium severity. It is exploitable over network with low attack complexity, requires no privileges and user interaction. Impact on confidentiality is low, integrity low, and availability none.
Is CVE-2024-0758 being actively exploited?
It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 1% (43rd percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2024-0758?
CVE-2024-0758 affects Ipb-halle Molecularfaces. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2024-0758?
Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround.
Does CVE-2024-0758 have an EU (EUVD) identifier?
Yes. CVE-2024-0758 is tracked in the ENISA EU Vulnerability Database (EUVD) as EUVD-2024-0445.
When was CVE-2024-0758 published?
CVE-2024-0758 was published on 2024-01-19 and last updated on 2026-06-17.

References

Affected products (1)

Other CWE-79 (Cross-site Scripting (XSS)) vulnerabilities

Browse all CWE-79 (Cross-site Scripting (XSS)) vulnerabilities →